| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sanjai Kumar | Q55838184 |
| P2093 | author name string | Dibyendu Dana | |
| P2860 | cites work | Structural basis for the recognition and cleavage of histone H3 by cathepsin L | Q24293301 |
| The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors | Q24300962 | ||
| The proteome of lysosomes | Q24303943 | ||
| Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor | Q24312357 | ||
| Structural and functional characterization of two allelic variants of human cystatin D sharing a characteristic inhibition spectrum against mammalian cysteine proteinases | Q24319696 | ||
| L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L | Q24531160 | ||
| Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment | Q24561952 | ||
| Secreted cathepsin L generates endostatin from collagen XVIII | Q24599981 | ||
| Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L | Q24678337 | ||
| Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors | Q26771736 | ||
| Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes | Q26827307 | ||
| Cysteine cathepsins: from structure, function and regulation to new frontiers | Q26860406 | ||
| Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex | Q27620728 | ||
| Azepanone-based inhibitors of human and rat cathepsin K | Q27631249 | ||
| Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides | Q27639963 | ||
| Crystal structure of the parasite protease inhibitor chagasin in complex with a host target cysteine protease | Q27645572 | ||
| Exploring inhibitor binding at the S' subsites of cathepsin L | Q27649866 | ||
| Crystal structure and silica condensing activities of silicatein α–cathepsin L chimeras | Q27650199 | ||
| Dipeptidyl nitrile inhibitors of Cathepsin L | Q27655858 | ||
| A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors | Q27657460 | ||
| Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors | Q27664560 | ||
| Systematic investigation of halogen bonding in protein-ligand interactions | Q27666413 | ||
| Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: efficient interactions in different environments | Q27673373 | ||
| Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L | Q27684569 | ||
| Caught in the act: the crystal structure of cleaved cathepsin L bound to the active site of Cathepsin L | Q27704273 | ||
| Cystatins | Q28180897 | ||
| The crystal structure of human cathepsin L complexed with E-64 | Q28237390 | ||
| The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor | Q28342303 | ||
| The use of benzyloxycarbonyl[125I]iodotyrosylalanyldiazomethane as a probe for active cysteine proteinases in human tissues | Q28354320 | ||
| The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B | Q28359859 | ||
| Clinical significance of cathepsin L and cathepsin B in dilated cardiomyopathy. | Q50959078 | ||
| Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide⋅⋅⋅Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket. | Q51251348 | ||
| Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery. | Q52950183 | ||
| Cathepsin-L contributes to cardiac repair and remodelling post-infarction. | Q54627475 | ||
| Selective imaging of cathepsin L in breast cancer by fluorescent activity-based probes. | Q55023666 | ||
| Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice | Q56993719 | ||
| pH-induced conformational transitions of the propeptide of human cathepsin L. A role for a molten globule state in zymogen activation | Q57220930 | ||
| UniProt: a worldwide hub of protein knowledge | Q58611634 | ||
| Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors | Q58842291 | ||
| Fluorine Scan of Inhibitors of the Cysteine Protease Human Cathepsin L: Dipolar and Quadrupolar Effects in the π-Stacking of Fluorinated Phenyl Rings on Peptide Amide Bonds | Q61066401 | ||
| Aziridide-Based Inhibitors of Cathepsin L: Synthesis, Inhibition Activity, and Docking Studies | Q61066429 | ||
| Rational Design of Aziridine-Containing Cysteine Protease Inhibitors with Improved Potency: Studies on Inhibition Mechanism | Q61066430 | ||
| New Peptidic Cysteine Protease Inhibitors Derived from the Electrophilic α-Amino Acid Aziridine-2,3-dicarboxylic Acid | Q61066437 | ||
| Crystallization and preliminary X-ray diffraction studies of human procathepsin L | Q64038879 | ||
| Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. | Q64885339 | ||
| Reactions between dipeptidyl peptidase IV and diacyl hydroxylamines: mechanistic investigations | Q69370125 | ||
| Evidence that aspartic proteinase is involved in the proteolytic processing event of procathepsin L in lysosomes | Q69505828 | ||
| Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity | Q28366301 | ||
| Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions | Q28505057 | ||
| Lysosomal enzyme phosphorylation. Recognition of a protein-dependent determinant allows specific phosphorylation of oligosaccharides present on lysosomal enzymes | Q28573945 | ||
| A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor | Q28592058 | ||
| Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1 | Q28594958 | ||
| Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus | Q28613227 | ||
| N-peptidyl-O-carbamoyl amino acid hydroxamates: irreversible inhibitors for the study of the S2' specificity of cysteine proteinases. | Q30321430 | ||
| Tight-binding inhibition of cathepsin S by cystatins | Q30321471 | ||
| Podocyte biology and pathogenesis of kidney disease | Q30424169 | ||
| In situ hybridization screen in zebrafish for the selection of genes encoding secreted proteins. | Q30781073 | ||
| Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. | Q31805262 | ||
| Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities | Q33235638 | ||
| Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L | Q33327656 | ||
| Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors | Q33525418 | ||
| Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L and B. | Q33638719 | ||
| Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse | Q33653550 | ||
| Finding enzymes that are actively involved in cancer | Q33664242 | ||
| Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models. | Q33920338 | ||
| The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. | Q33943247 | ||
| The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. | Q34009651 | ||
| Cathepsin L is essential for onset of autoimmune diabetes in NOD mice | Q34014524 | ||
| Strategies for discovering and derisking covalent, irreversible enzyme inhibitors | Q34023143 | ||
| Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. | Q34028619 | ||
| A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. | Q34051627 | ||
| Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes | Q34078522 | ||
| The resurgence of covalent drugs | Q34174891 | ||
| Activity-based probes for protein tyrosine phosphatases | Q34330552 | ||
| The lysosome turns fifty | Q34447595 | ||
| Distinct roles for cysteine cathepsin genes in multistage tumorigenesis | Q34471105 | ||
| Cysteine cathepsins and the cutting edge of cancer invasion | Q34605340 | ||
| Biogenesis and proteolytic processing of lysosomal DNase II | Q34630331 | ||
| Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors? | Q34657266 | ||
| Cathepsin inhibition-induced lysosomal dysfunction enhances pancreatic beta-cell apoptosis in high glucose | Q35019204 | ||
| Potent and selective inactivation of proteinases with N-peptidyl-O-acylhydroxylamines | Q69510216 | ||
| Dipeptidylpeptidase IV--inactivation with N-peptidyl-O-aroyl hydroxylamines | Q69931019 | ||
| Cathepsin B-related proteases in the insulin secretory granule | Q70213567 | ||
| N,O-diacylhydroxylamines as enzyme-activated inhibitors for serine proteases | Q70265656 | ||
| Novel N-peptidyl-O-acyl hydroxamates: selective inhibitors of cysteine proteinases | Q70481053 | ||
| In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator | Q70494598 | ||
| Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases | Q71185919 | ||
| Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo | Q71348149 | ||
| Aziridine Analogs of [[trans-(Epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as Inhibitors of Cysteine Proteases | Q71963258 | ||
| Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo | Q73077056 | ||
| Relative rates of Michael reactions of 2'-(phenethyl)thiol with vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfonyl cysteine protease inhibitors | Q73428095 | ||
| Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption | Q74095795 | ||
| Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B | Q74151522 | ||
| Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption | Q77449793 | ||
| Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone | Q80182629 | ||
| Parkinson's disease involves autophagy and abnormal distribution of cathepsin L | Q82753888 | ||
| Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment | Q84312844 | ||
| Microarray-guided discovery of two-photon (2P) small molecule probes for live-cell imaging of cysteinyl cathepsin activities | Q84404193 | ||
| Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent | Q84512759 | ||
| A novel photoaffinity-based probe for selective detection of cathepsin L active form | Q85356487 | ||
| Expression of a zebrafish Cathepsin L gene in anterior mesendoderm and hatching gland | Q88564623 | ||
| Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain | Q90189749 | ||
| Cysteine Cathepsins in Tumor-Associated Immune Cells | Q90290679 | ||
| Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis | Q91134523 | ||
| Cell penetrable, clickable and tagless activity-based probe of human cathepsin L | Q91893901 | ||
| Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease | Q39066800 | ||
| Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB | Q39412077 | ||
| Real-time monitoring of drug release | Q39753844 | ||
| Cathepsin L expression is up-regulated by hypoxia in human melanoma cells: role of its 5'-untranslated region. | Q39998490 | ||
| Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. | Q40080774 | ||
| Toolbox of Fluorescent Probes for Parallel Imaging Reveals Uneven Location of Serine Proteases in Neutrophils. | Q40149159 | ||
| Global analysis of protein tyrosine phosphatase activity with ultra-sensitive fluorescent probes. | Q40247455 | ||
| Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. | Q40268385 | ||
| Activity-based probes that target diverse cysteine protease families | Q40330849 | ||
| Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin | Q40545315 | ||
| Lysosomal acid phosphatase is transported to lysosomes via the cell surface | Q40822199 | ||
| Antimicrobial Peptide LL-37 Is Both a Substrate of Cathepsins S and K and a Selective Inhibitor of Cathepsin L. | Q41056650 | ||
| Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype | Q41265835 | ||
| Inhibition of cysteine proteinases in lysosomes and whole cells | Q41613431 | ||
| Cystatin-like cysteine proteinase inhibitors from human liver | Q41868134 | ||
| Molecular docking of cathepsin L inhibitors in the binding site of papain | Q41889166 | ||
| E64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane] analogues as inhibitors of cysteine proteinases: investigation of S2 subsite interactions | Q42084932 | ||
| Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. | Q42273053 | ||
| Multiple Cathepsins Promote Pro-IL-1β Synthesis and NLRP3-Mediated IL-1β Activation | Q42428279 | ||
| Quantification of cathepsins B and L in cells | Q42537421 | ||
| Potent and selective inactivation of cysteine proteinases with N-peptidyl-O-acyl hydroxylamines | Q42804251 | ||
| Dynamic imaging of protease activity with fluorescently quenched activity-based probes. | Q42806191 | ||
| Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases | Q42852932 | ||
| Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. | Q42864053 | ||
| Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. | Q42981725 | ||
| Cysteine protease inhibition by azapeptide esters | Q43428037 | ||
| Splice variants of human cathepsin L mRNA show different expression rates | Q43840167 | ||
| Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes | Q44564070 | ||
| Cathepsin L is crucial for a Th1-type immune response during Leishmania major infection. | Q44862470 | ||
| Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy | Q44904231 | ||
| Comprehensive search for cysteine cathepsins in the human genome | Q44935351 | ||
| Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate | Q44935373 | ||
| Peptidyl (acyloxy)methanes as quiescent affinity labels for cysteine proteinases | Q45304042 | ||
| Optimization of a Protease Activated Probe for Optical Surgical Navigation. | Q45933355 | ||
| A cathepsin L-specific inhibitor preferentially inhibits degradation of autophagosomal LC3 and GABARAP in HeLa and Huh-7 cells. | Q45964739 | ||
| Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. | Q46006433 | ||
| Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors | Q46097132 | ||
| Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling | Q46190199 | ||
| High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells | Q46488605 | ||
| Azepanone-based inhibitors of human cathepsin L. | Q46775748 | ||
| Cell type-specific functions of the lysosomal protease cathepsin L in the heart | Q46945604 | ||
| Zebrafish KLF4 is essential for anterior mesendoderm/pre-polster differentiation and hatching | Q47073901 | ||
| The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease. | Q47171560 | ||
| Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors. | Q48045269 | ||
| Autophagic neuron death | Q48745538 | ||
| Cysteine cathepsins in extracellular matrix remodeling: Extracellular matrix degradation and beyond. | Q50057748 | ||
| Lysosomal cysteine proteases (cathepsins): promising drug targets. | Q35055535 | ||
| Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. | Q35234967 | ||
| Redundancy between Cysteine Cathepsins in Murine Experimental Autoimmune Encephalomyelitis | Q35663877 | ||
| Protease-activated drug development | Q35811508 | ||
| Complete and limited proteolysis in cell cycle progression. | Q35836775 | ||
| An Active 32-kDa Cathepsin L Is Secreted Directly from HT 1080 Fibrosarcoma Cells and Not via Lysosomal Exocytosis | Q35870565 | ||
| Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease | Q35916157 | ||
| Multiple roles for cysteine cathepsins in cancer | Q35946770 | ||
| Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-Like Cholesterol Sequestration and Accumulation of the Key Alzheimer's Proteins | Q36208265 | ||
| Cathepsin L targeting in cancer treatment. | Q36218199 | ||
| The tick salivary protein sialostatin L inhibits the Th9-derived production of the asthma-promoting cytokine IL-9 and is effective in the prevention of experimental asthma. | Q36470838 | ||
| Cysteine cathepsins: multifunctional enzymes in cancer | Q36600996 | ||
| Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. | Q36775345 | ||
| Homing and engraftment of progenitor cells: a prerequisite for cell therapy | Q37096297 | ||
| Plasma levels of cathepsins L, K, and V and risks of abdominal aortic aneurysms: a randomized population-based study. | Q37118040 | ||
| Activity-based protein profiling: from enzyme chemistry to proteomic chemistry | Q37119021 | ||
| Dynamin rings: not just for fission | Q37315491 | ||
| Regulation of cell proliferation and differentiation in the kidney. | Q37359013 | ||
| Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts | Q37588423 | ||
| The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L. | Q37598633 | ||
| Identification of a 31,500 molecular weight islet cell protease as cathepsin B | Q37613242 | ||
| Cathepsin L, target in cancer treatment? | Q37643875 | ||
| Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back | Q37677400 | ||
| Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. | Q37735722 | ||
| Homing of progenitor cells to ischemic tissues | Q37784827 | ||
| Specialized roles for cysteine cathepsins in health and disease. | Q37797839 | ||
| Activity-based profiling of proteases | Q38218232 | ||
| Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response | Q38644547 | ||
| The Future of Cysteine Cathepsins in Disease Management | Q38664101 | ||
| Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L. | Q38766492 | ||
| Development of a highly potent, selective, and cell-active inhibitor of cysteine cathepsin L-A hybrid design approach. | Q38969005 | ||
| Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins | Q38983504 | ||
| Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor | Q39035003 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P577 | publication date | 2020-02-06 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L | |
| P478 | volume | 25 |
| Q108502694 | Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development |
| Q96017828 | Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients |
| Q94672407 | Coumarin as a structural component of substrates and probes for serine and cysteine proteases |
| Q96352766 | Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities |
| Q99637358 | Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2 |
| Q98389656 | SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells |
Search more.